{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:39:40Z","timestamp":1793367580343,"version":"4.5.0"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead G.K."},{"name":"Asahikasei Pharma"},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan Tobacco"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi-Tanabe Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytokines are critical mediators of diverse immune and inflammatory diseases. Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance. We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents. Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases. We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs.<\/jats:p>","DOI":"10.1093\/rheumatology\/key432","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T21:46:08Z","timestamp":1548798368000},"page":"i4-i16","source":"Crossref","is-referenced-by-count":141,"title":["Janus kinases to jakinibs: from basic insights to clinical practice"],"prefix":"10.1093","volume":"58","author":[{"given":"Massimo","family":"Gadina","sequence":"first","affiliation":[{"name":"Translational Immunology Section, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi T","family":"Le","sequence":"additional","affiliation":[{"name":"Translational Immunology Section, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella M","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Molecular Immunology and Inflammation Branch, National Institute of Arthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Silvennoinen","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, University of Helsinki, Helsinki, Finland"},{"name":"Faculty of Medicine and Life Sciences, Fimlab Laboratories University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Disease, Kitasato University, School of Medicine, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"Molecular Immunology and Inflammation Branch, National Institute of Arthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"2019072508201023400_key432-B1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/179633a0","article-title":"Role of the kidney in erythropoiesis","volume":"179","author":"Jacobson","year":"1957","journal-title":"Nature"},{"key":"2019072508201023400_key432-B2","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2174\/1381612043382611","article-title":"Common structural stability properties of 4-helical bundle cytokines: possible physiological and pharmaceutical consequences","volume":"10","author":"Ricci","year":"2004","journal-title":"Curr Pharm Des"},{"key":"2019072508201023400_key432-B3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"2019072508201023400_key432-B4","article-title":"TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state. Sci Signal","volume":"11","author":"Rochman","year":"2018"},{"key":"2019072508201023400_key432-B5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imr.12546","article-title":"The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines","volume":"278","author":"Han","year":"2017","journal-title":"Immunol Rev"},{"key":"2019072508201023400_key432-B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1600372","article-title":"Evolution of cytokine receptor signaling","volume":"197","author":"Liongue","year":"2016","journal-title":"J Immunol"},{"key":"2019072508201023400_key432-B7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2019072508201023400_key432-B8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fimmu.2013.00396","article-title":"Ligands and receptors of the interleukin-1 family in immunity and disease","volume":"4","author":"Garlanda","year":"2013","journal-title":"Front Immunol"},{"key":"2019072508201023400_key432-B9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: the yin and the yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol"},{"key":"2019072508201023400_key432-B10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"2019072508201023400_key432-B11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"2019072508201023400_key432-B12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0968-0004(94)90026-4","article-title":"Signaling by the cytokine receptor superfamily: JAKs and STATs","volume":"19","author":"Ihle","year":"1994","journal-title":"Trends Biochem Sci"},{"key":"2019072508201023400_key432-B13","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2015-01-621110","article-title":"Molecular insights into regulation of JAK2 in myeloproliferative neoplasms","volume":"125","author":"Silvennoinen","year":"2015","journal-title":"Blood"},{"key":"2019072508201023400_key432-B14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/acsmedchemlett.7b00153","article-title":"Identification and characterization of JAK2 pseudokinase domain small molecule binders","volume":"8","author":"Puleo","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"2019072508201023400_key432-B15","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","article-title":"Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain","volume":"290","author":"Tokarski","year":"2015","journal-title":"J Biol Chem"},{"key":"2019072508201023400_key432-B16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"2019072508201023400_key432-B17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","article-title":"A protein tyrosine kinase in the interferon \u03b1\/\u03b2 signaling pathway","volume":"70","author":"Velazquez","year":"1992","journal-title":"Cell"},{"key":"2019072508201023400_key432-B18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-065X.1994.tb00847.x","article-title":"The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c","volume":"138","author":"Leonard","year":"1994","journal-title":"Immunol Rev"},{"key":"2019072508201023400_key432-B19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"2019072508201023400_key432-B20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"2019072508201023400_key432-B21","first-page":"39","article-title":"Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency","volume":"178","author":"Notarangelo","year":"2000","journal-title":"Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev"},{"key":"2019072508201023400_key432-B22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"Akada","year":"2014","journal-title":"Stem Cells"},{"key":"2019072508201023400_key432-B23","doi-asserted-by":"crossref","first-page":"e59675","DOI":"10.1371\/journal.pone.0059675","article-title":"Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans","volume":"8","author":"Park","year":"2013","journal-title":"PLoS One"},{"key":"2019072508201023400_key432-B24","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2014-03-560441","article-title":"Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis","volume":"124","author":"Meyer","year":"2014","journal-title":"Blood"},{"key":"2019072508201023400_key432-B25","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2014-08-596361","article-title":"Less Jak2 makes more platelets","volume":"124","author":"Skoda","year":"2014","journal-title":"Blood"},{"key":"2019072508201023400_key432-B26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1523\/JNEUROSCI.2974-10.2011","article-title":"Jak2 is necessary for neuroendocrine control of female reproduction","volume":"31","author":"Wu","year":"2011","journal-title":"J Neurosci"},{"key":"2019072508201023400_key432-B27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"2019072508201023400_key432-B28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.stem.2017.08.011","article-title":"Jak1 integrates cytokine sensing to regulate hematopoietic stem cell function and stress hematopoiesis","volume":"21","author":"Kleppe","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2019072508201023400_key432-B29","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.4049\/jimmunol.176.12.7263","article-title":"Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-\u03b3-dependent IL-10 reactivation","volume":"176","author":"Shaw","year":"2006","journal-title":"J Immunol"},{"key":"2019072508201023400_key432-B30","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.4049\/jimmunol.1402565","article-title":"Intestinal epithelial cell tyrosine kinase 2 transduces IL-22 signals to protect from acute colitis","volume":"195","author":"Hainzl","year":"2015","journal-title":"J Immunol"},{"key":"2019072508201023400_key432-B31","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J Exp Med"},{"key":"2019072508201023400_key432-B32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1126\/science.7541555","article-title":"Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein","volume":"269","author":"Yu","year":"1995","journal-title":"Science"},{"key":"2019072508201023400_key432-B33","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/bjc.1995.162","article-title":"Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts","volume":"71","author":"Watson","year":"1995","journal-title":"Br J Cancer"},{"key":"2019072508201023400_key432-B34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.7604283","article-title":"Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I","volume":"269","author":"Migone","year":"1995","journal-title":"Science"},{"key":"2019072508201023400_key432-B35","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood.V87.5.1692.1692","article-title":"STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients","volume":"87","author":"Gouilleux-Gruart","year":"1996","journal-title":"Blood"},{"key":"2019072508201023400_key432-B36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tibs.2007.12.002","article-title":"Mining for JAK-STAT mutations in cancer","volume":"33","author":"Constantinescu","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"2019072508201023400_key432-B37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas","year":"2015","journal-title":"Br J Cancer"},{"key":"2019072508201023400_key432-B38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2017.276","article-title":"Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK\/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia","volume":"32","author":"Degryse","year":"2018","journal-title":"Leukemia"},{"key":"2019072508201023400_key432-B39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev-pathol-012615-044454","article-title":"Pathogenesis of myeloproliferative disorders","volume":"11","author":"Nangalia","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"2019072508201023400_key432-B40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","article-title":"Primary myelofibrosis: update on definition, pathogenesis, and treatment","volume":"60","author":"Abdel-Wahab","year":"2009","journal-title":"Annu Rev Med"},{"key":"2019072508201023400_key432-B41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.seminhematol.2005.05.019","article-title":"Role of tyrosine kinases and phosphatases in polycythemia vera","volume":"42","author":"Zhao","year":"2005","journal-title":"Semin Hematol"},{"key":"2019072508201023400_key432-B42","doi-asserted-by":"crossref","first-page":"a028555","DOI":"10.1101\/cshperspect.a028555","article-title":"Responses to cytokines and interferons that depend upon JAKs and STATs","volume":"10. pii","author":"Stark","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2019072508201023400_key432-B43","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019072508201023400_key432-B44","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2010-12-319467","article-title":"FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia\/lymphoma","volume":"118","author":"Elliott","year":"2011","journal-title":"Blood"},{"key":"2019072508201023400_key432-B45","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"2019072508201023400_key432-B46","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/art.40216","article-title":"Genome-wide association meta-analysis reveals novel juvenile idiopathic arthritis susceptibility loci","volume":"69","author":"McIntosh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B47","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s11033-010-0601-5","article-title":"Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases","volume":"38","author":"Tao","year":"2011","journal-title":"Mol Biol Rep"},{"key":"2019072508201023400_key432-B48","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.1203118","article-title":"Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent","volume":"190","author":"Li","year":"2013","journal-title":"J Immunol"},{"key":"2019072508201023400_key432-B49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.humimm.2012.09.007","article-title":"TYK2 rs34536443 polymorphism is associated with a decreased susceptibility to endometriosis-related infertility","volume":"74","author":"Peluso","year":"2013","journal-title":"Hum Immunol"},{"key":"2019072508201023400_key432-B50","doi-asserted-by":"crossref","first-page":"e0122271","DOI":"10.1371\/journal.pone.0122271","article-title":"TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits","volume":"10","author":"Diogo","year":"2015","journal-title":"PLoS One"},{"key":"2019072508201023400_key432-B51","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2019072508201023400_key432-B52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ni.2845","article-title":"A role for the ITAM signaling module in specifying cytokine-receptor functions","volume":"15","author":"Bezbradica","year":"2014","journal-title":"Nat Immunol"},{"key":"2019072508201023400_key432-B53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"2019072508201023400_key432-B54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B55","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2019072508201023400_key432-B56","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1586\/1744666X.2014.918847","article-title":"Intravenous golimumab in rheumatoid arthritis","volume":"10","author":"Cohen","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2019072508201023400_key432-B57","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2019072508201023400_key432-B58","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2016-209821","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib in patients with rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor inhibitors","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2019072508201023400_key432-B60","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2015-eular.1427","article-title":"Baricitinib, an oral Janus kinase (JAK)1\/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the phase 3 RA-BEACON study","volume":"74","author":"Genovese","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B61","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B62","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","article-title":"Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B63","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B64","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jama.2011.67","article-title":"Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans","volume":"305","author":"Schmajuk","year":"2011","journal-title":"JAMA"},{"key":"2019072508201023400_key432-B66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B67","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in rheumatoid arthritis patients before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B68","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2019072508201023400_key432-B69","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"2019072508201023400_key432-B70","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/kex068","article-title":"Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study","volume":"56","author":"Kubo","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2019072508201023400_key432-B71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2019072508201023400_key432-B72","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B73","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"2019072508201023400_key432-B74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B75","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B76","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B77","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.40036","article-title":"Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis","volume":"69","author":"Kremer","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B78","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","article-title":"Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study","volume":"37","author":"Kume","year":"2017","journal-title":"Rheumatol Int"},{"key":"2019072508201023400_key432-B79","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2017.09.076","article-title":"T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate to severe psoriasis during tofacitinib treatment","volume":"78","author":"Winthrop","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2019072508201023400_key432-B80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT\u2014emerging players in metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"2019072508201023400_key432-B81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcdb.2016.02.009","article-title":"STAT3 in the systemic inflammation of cancer cachexia","volume":"54","author":"Zimmers","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"2019072508201023400_key432-B82","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"2019072508201023400_key432-B83","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2019072508201023400_key432-B84","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.120687","article-title":"Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure","volume":"40","author":"Genovese","year":"2013","journal-title":"J Rheumatol"},{"key":"2019072508201023400_key432-B85","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690, 550: a pilot study in de novo kidney allograft recipients","volume":"9","author":"Busque","year":"2009","journal-title":"Am J Transplant"},{"key":"2019072508201023400_key432-B86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/acr.23421","article-title":"Lymphoma in the tofacitinib rheumatoid arthritis clinical development program","volume":"70","author":"Mariette","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2019072508201023400_key432-B87","first-page":"614","article-title":"Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme","volume":"35","author":"Curtis","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B88","first-page":"abstract 1048","article-title":"Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study","volume":"67","author":"Westhovens","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/annrheumdis-2017-211871","article-title":"Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis","volume":"77","author":"Kavanaugh","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B90","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B91","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B92","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"2019072508201023400_key432-B93","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"2019072508201023400_key432-B94","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"2019072508201023400_key432-B95","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"2019072508201023400_key432-B96","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2019072508201023400_key432-B97","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B98","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1136\/annrheumdis-2015-208901","article-title":"Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings","volume":"75","author":"Genovese","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019072508201023400_key432-B99","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1124\/dmd.116.071100","article-title":"VX-509 (decernotinib)-mediated CYP3A time-dependent inhibition: an aldehyde oxidase metabolite as a perpetrator of drug-drug interactions","volume":"44","author":"Zetterberg","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"2019072508201023400_key432-B101","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J Med Chem"},{"key":"2019072508201023400_key432-B102","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/mi.2017.38","article-title":"Jak3 deficiency blocks innate lymphoid cell development","volume":"11","author":"Robinette","year":"2018","journal-title":"Mucosal Immunol"},{"key":"2019072508201023400_key432-B103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.116.239723","article-title":"Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor","volume":"361","author":"Elwood","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"2019072508201023400_key432-B104","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem Biol"},{"key":"2019072508201023400_key432-B105","first-page":"abstract 888","article-title":"Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to methotrexate [abstract]","volume":"70","author":"Takeuchi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2019072508201023400_key432-B106","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fimmu.2012.00132","article-title":"Post-ischemic inflammation in the brain","volume":"3","author":"Shichita","year":"2012","journal-title":"Front Immunol"},{"key":"2019072508201023400_key432-B107","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.molmed.2006.12.002","article-title":"Role of the JAK-STAT pathway in myocardial injury","volume":"13","author":"Barry","year":"2007","journal-title":"Trends Mol Med"},{"key":"2019072508201023400_key432-B108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","article-title":"A case series on patients on tofacitinib in combination with a biologic","volume":"24","author":"Barroso","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2019072508201023400_key432-B109","first-page":"349","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"24","author":"Kleppe","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2019072508201023400_key432-B110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J Clin Invest"},{"key":"2019072508201023400_key432-B111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fendo.2017.00361","article-title":"Mechanistic insights into regulation of JAK2 tyrosine kinase","volume":"8","author":"Hubbard","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2019072508201023400_key432-B112","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2017.08.010","article-title":"A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia","volume":"61","author":"Verstovsek","year":"2017","journal-title":"Leuk Res"},{"key":"2019072508201023400_key432-B113","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"2019072508201023400_key432-B114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/Supplement_1\/i4\/28999318\/key432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:24:13Z","timestamp":1590009853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/Supplement_1\/i4\/5365420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":114,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key432","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}